Holen Sie sich die Stockscreener-App
41.46
1.20%
0.49
Handel nachbörslich:
41.46
Schlusskurs vom Vortag:
$40.97
Offen:
$41.05
24-Stunden-Volumen:
517.13K
Relative Volume:
0.66
Marktkapitalisierung:
$2.02B
Einnahmen:
$140.49M
Nettoeinkommen (Verlust:
$-153.49M
KGV:
-15.05
EPS:
-2.7551
Netto-Cashflow:
$-175.90M
1W Leistung:
+0.83%
1M Leistung:
+20.03%
6M Leistung:
+89.75%
1J Leistung:
+118.79%
1-Tages-Spanne:
$40.10
$41.96
1-Wochen-Bereich:
$40.10
$43.93
52-Wochen-Spanne:
$15.86
$43.93
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
41.46 | 2.00B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Operating expenses (excl. COGS) of UroGen Pharma Ltd. – HAM:UR8 - TradingView
UroGen Pharma Ltd. Revenue Breakdown – HAM:UR8 - TradingView
Urogen Pharma Ltd (URGN) Institutional Confidence - TradingKey
Price to earnings forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to earnings forward of UroGen Pharma Ltd. – FWB:UR8 - TradingView
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
(URGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
URGN Maintained by Guggenheim -- Price Target Raised to $42 - GuruFocus
URGN stock trades steady as UroGen revenue grows and pipeline advances - Ad-hoc-news.de
What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders - simplywall.st
Enterprise value to revenue forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to sales forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN) - Seeking Alpha
Price to earnings forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma (URGN) AGM 2026 Summary - Quartr
What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs - Kavout | AI
UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow - simplywall.st
Urogen Pharma stock hits 52-week high at 41.45 USD By Investing.com - Investing.com South Africa
ETFs Investing in UroGen Pharma Ltd. Stocks - TradingView
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027 - Barchart.com
Urogen Pharma stock hits 52-week high at 41.45 USD - Investing.com
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news - Investing.com UK
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
URGN Maintained by Oppenheimer -- Price Target Raised to $50 - GuruFocus
Oppenheimer Adjusts Price Target on UroGen Pharma to $50 From $40, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook - Investing.com Canada
UroGen Pharma (URGN) Secures Patent Approval for Bladder Cancer Treatment - GuruFocus
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44 - 富途牛牛
UroGen receives US patent allowance for bladder cancer treatment - Investing.com UK
Should I Buy URGN (UroGen Pharma Ltd.) | AI Analysis, Technical & News Insights - Kavout | AI
UroGen receives US patent allowance for bladder cancer treatment By Investing.com - Investing.com Nigeria
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 - The Manila Times
UroGen Receives New U.S. Patent Allowance Expected to - GlobeNewswire
UroGen patent allowance covers bladder cancer care without tumor resection - Stock Titan
URGN Stock Price, Quote & Chart - ChartMill
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - BioBuzz
UroGen receives FDA clearance for bladder cancer trial By Investing.com - Investing.com Nigeria
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial - Sahm
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares By Investing.com - Investing.com Australia
Form 4 Urogen Pharma Ltd For: 10 July By Investing.com - Investing.com India
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares - Investing.com
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):